Diabetic ketoacidosis (DKA) is an acutely life-threatening complication of diabetes mellitus that occurs predominantly in type 1 diabetes, but is also increasingly occurring in people with type 2 diabetes. A special form is euglycemic DKA, which mainly occurs during therapy with SGLT2 inhibitors. Even though it has become rare and the mortality rate is now only just over 1%, these deaths are usually preventable. Timely diagnosis, standardized treatment protocols and, above all, prophylaxis are crucial for the prognosis.
Autoren
- Toralf Schwarz
Publikation
- CARDIOVASC
Related Topics
You May Also Like
- Secondary prevention after ACS: individually optimized lipid management
Trend towards early combination therapy and new strategies for lowering Lp(a)
- Pediatric Brain Tumors
Psychiatry versus Neuro-Oncology: Diagnostic Pitfalls
- What the latest studies on the entire EF spectrum mean for clinical practice
Heart Failure – The 2026 Evidence Update
- Acute ischemic stroke
Alteplase and Tenecteplase Are on the Same Level
- CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment
SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes
- Wearables: screening via smartwatch?
New study on atrial fibrillation in high-risk patients
- Peristomal skin health
Focus on preventive care options
- Planning a Family, Pregnancy, and Breastfeeding